Research Nester released a report titled “Hematology Diagnostics Market: Global Demand Analysis & Opportunity Outlook 2027” which delivers detailed overview of the global hematology diagnostics market in terms of market segmentation by product, by portability, by application, by end user and by region.

Further, for the in-depth analysis, the report encompasses the industry growth drivers, restraints, supply and demand risk, market attractiveness, BPS analysis and Porter’s five force model.

Hematology diagnostics is the testing of blood in order to measure the number of blood cells for the identification of any disorder related to the blood. The market for hematology diagnostics is projected to grow with a CAGR of 6.06% during the forecast period, i.e., 2020-2027. This can be attributed to the increasing demand for advanced medical technologies for diagnostics across the world. The market is segmented by product, by portability, by application, by end user and by region. On the basis of product, the market is segmented into reagents, instruments & analyzers and software & services, out of which, the reagent segment is anticipated to hold the largest share of 60% in the hematology diagnostics market on account of low cost of production, growing availability of reagents for specific analyzer tests and increasing demand for tests by people.

The global hematology diagnostics market is segmented by regions into North America, Latin America, Europe, Asia-Pacific and Middle East and Africa. The market in North America is estimated to grow at the highest rate as a result of growing investments by government and private organizations in the healthcare industry, mainly in the United States. The U.S. hematology diagnostics market is predicted to grow by a CAGR of 6.23% over the forecast period on account of higher availability of advanced healthcare technologies in the region.

Growing Prevalence of Blood Disorders to Boost the Market Growth

The rising incidence of blood and blood related disorders are anticipated to be major growth drivers for the market on account of growing demand for blood tests that help identify and detect the disease. According to UNAIDS, there were about 37.9 million people living with HIV in 2018, out of which, 36.2 million were adults and 1.7 million were children under the age of 15 years. Apart from this, the growing cases of leukemia, malaria, anemia and other such disorders is further estimated to increase the scope of this market. However, the unfavorable government policies and regulations that result in low reimbursement rates and decrease in number of doctors accepting Medicaid patients is predicted to become a barrier for the market growth in the upcoming years.

This report also provides the existing competitive scenario of some of the key players of the global hematology diagnostics market which includes company profiling of F. Hoffmann-La Roche Ltd (SWX: ROG), Abbott (NYSE: ABT), Sysmex (TYO: 6869), Beckman Coulter, Inc. (NYSE:BEC), Siemens Healthineers AG (ETR: SHL), Boule Diagnostics A (STO: BOUL), Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (SHE: 300760), Bio-Rad Laboratories, Inc. (NYSE: BIO) and Cellavision (STO: CEVI). The profiling enfolds key information of the companies which encompasses business overview, products and services, key financials and recent news and developments. On the whole, the report depicts detailed overview of the global hematology diagnostics market that will help industry consultants, equipment manufacturers, existing players searching for expansion opportunities, new players searching possibilities and other stakeholders to align their market centric strategies according to the ongoing and expected trends in the future.